Lowering dose of JAK inhibitors for rheumatoid arthritis or psoriatic arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests if reducing the dose of a JAK inhibitor can keep your inflammatory arthritis under control. If you have rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis and are in a stable remission, you may be able to take a lower dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older
- You have rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis (a type of inflammatory arthritis)
- You have been taking a JAK inhibitor (a type of targeted medicine) for at least 6 months and it has kept your disease activity low or in remission
- You are not pregnant and do not plan to become pregnant during the study
- You do not have other serious health conditions like active Crohn's disease or ulcerative colitis that require ongoing JAK inhibitor treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
This trial tests taking a JAK inhibitor (a type of pill that helps calm inflammation in rheumatoid arthritis) by mouth. It aims to see how well it works and if it's safe for people with RA who need this kind of medicine.
This study compares two different ways of slowly lowering the dose of steroids (like prednisolone) in people with stable rheumatoid arthritis. The goal is to see which tapering schedule is safer and more effective, possibly reducing side effects while keeping the disease under control.
This study tests a new, AI-powered treatment approach for rheumatoid arthritis. It's for people with active disease who haven't used certain biologic or targeted therapies in the last 6 months.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.